Vyant Bio, Inc. (OTC: VYNT) announced completing its asset sale on July 13, 2023. The company now focuses solely on winding down and closing its business, seeking shareholder approval for voluntary liquidation and dissolution. Relevant materials, including a proxy statement detailing the transaction and dissolution plan, are filed with the SEC and are critical for investors and security holders. These documents are available on the SEC website and Vyant Bio’s site for further details.
Vyant Bio, Inc. (“Vyant Bio” or “Company”) (OTC: VYNT) announced that it has completed the sale of all or substantially all of the assets of the Company (the “Sale”) under an Asset Purchase Agreement dated July 13, 2023.
ABOUT VYANT BIO, INC.
Vyant Bio, Inc. (OTC: VYNT) has no continuing operating activities other than the winddown and closure of its business. The Company is currently seeking to obtain its shareholders’ approval for the voluntary liquidation and dissolution of the Company, under a Plan of Liquidation and Dissolution.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Additional Information and Where to Find It
In connection with the transaction, Vyant Bio filed relevant materials with the Securities and Exchange Commission (the “SEC”), including a proxy statement. INVESTORS AND SECURITY HOLDERS OF VYANT BIO ARE URGED TO READ THESE MATERIALS CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY CONTAIN IMPORTANT INFORMATION ABOUT THE TRANSACTION AND RELATED MATTERS. The proxy statement and any other documents filed by Vyant Bio with the SEC may be obtained free of charge at the SEC website at www.sec.gov.
Source: Biospace